Kevin Bitterman, Ph.D.
Partner, Atlas Venture
As a Partner at Atlas Venture, Kevin focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO), Kinaset Therapeutics and Curie Therapeutics. He is a co-founder and board member of Disc Medicine, and is chair of the board of Remix Therapeutics and Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic (NASDAQ: MORF) and Visterra (acquired by Otsuka). Kevin previously served as a director of Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics (NASDAQ: STIM) and Taris Biomedical (acquired by Johnson & Johnson) among other ventures. Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004.